Caboxen 20 mg | Generic Cabozantinib by Everest Pharmaceuticals

Description

Dr. Daria KwaśniewskaESMO Certified Consultant Medical Oncologist

Reviewed June 2026

⚠ Prescription required. For informational purposes only. Meds For Cancer is a Named Patient Program facilitator — not a retail pharmacy. A valid oncologist prescription is mandatory before any order is processed.

Is Caboxen 20 mg right for your situation?

Review these criteria with your oncologist before enquiring

✔ You may be a candidate if

✓Advanced renal cell carcinoma (RCC), first-line or after prior therapy
✓Hepatocellular carcinoma (HCC) previously treated with sorafenib
✓Progressive, metastatic medullary thyroid cancer (MTC)
✓Need a WHO-GMP generic alternative to Cabometyx® (Exelixis)

✖ May NOT be suitable if

✗Recent severe bleeding, or unhealed surgical wounds
✗Surgery (including dental) planned within 28 days
✗Pregnant, planning pregnancy, or breastfeeding
✗Uncontrolled hypertension

Check Availability & Pricing

Prescription required · Named Patient Program · Worldwide shipping

💬 WhatsApp: +880 130 449 8958 ✉ Email: info@medsforcancer.com

🛡 WHO-GMP Certified · Prescription verified · Express dispatch

What is Caboxen 20 mg?

Caboxen 20 mg is a generic formulation of Cabozantinib — a multi-target tyrosine kinase inhibitor — manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP certified conditions in Bangladesh. Each capsule contains 20 mg of cabozantinib, the same active molecule found in Cabometyx® (Exelixis), and is dispensed under the Named Patient Program.

Cabozantinib is FDA-approved across three distinct cancer types — kidney, liver, and thyroid — each with its own specific dosing regimen and clinical evidence base.

Generic name	Cabozantinib (as the S-malate salt)
Reference brand	Cabometyx® (Exelixis)
Manufacturer	Everest Pharmaceuticals Ltd.
Standard	WHO-GMP Certified
Drug class	Multi-target Tyrosine Kinase Inhibitor
Dosage form	Capsule — 20 mg
Route	Oral · once daily, fasting
Prescription	Required — oncologist only

How Cabozantinib Works

Cabozantinib blocks multiple tyrosine kinases involved in tumour growth, angiogenesis, and metastasis, including VEGFR-2, MET, and RET — a broader target profile than single-pathway inhibitors.

By inhibiting VEGFR-2, cabozantinib cuts off new blood vessel formation that tumours need to grow. Simultaneous inhibition of MET and AXL — pathways often implicated in resistance to other VEGFR inhibitors — helps address one of the common ways kidney and liver cancers escape anti-angiogenic therapy. RET inhibition is specifically relevant for medullary thyroid cancer, where RET mutations frequently drive tumour growth. NCCN guidelines include cabozantinib as a preferred option across RCC, HCC, and MTC treatment pathways.

Side Effects

Cabozantinib carries several serious warnings that require careful monitoring throughout treatment.

Common · Usually Manageable

Diarrhoea
Hand-foot skin reaction
Hypertension
Fatigue
Decreased appetite
Nausea

Serious · Report Immediately

Severe gastrointestinal perforation or fistula
Serious haemorrhage
Thrombotic events (blood clots, stroke, heart attack)
Impaired wound healing
Osteonecrosis of the jaw
Hepatotoxicity

⚠ Call your doctor immediately if you experience:

Severe abdominal pain (possible GI perforation)
Unusual bleeding, coughing/vomiting blood, or blood in stool
Sudden chest pain, weakness, or difficulty speaking
Jaw pain, swelling, or numbness (possible osteonecrosis)

How to Take Caboxen 20 mg

Standard adult dose: 60 mg once daily (built from capsule combinations totalling 60 mg) for RCC and HCC, or 140 mg once daily for MTC. Always follow your exact prescribed dose.

1
Take on an empty stomach — at least 1 hour before or 2 hours after eating, for consistent absorption.
2
Swallow capsule whole with water. Do not crush or chew.
3
Discontinue at least 28 days before any scheduled surgery, including dental procedures, due to wound-healing risk. Do not resume until the wound has fully healed, as confirmed by your surgeon.
4
If you miss a dose, skip it if the next dose is due within 12 hours — do not double up.
5
Storage: room temperature, dry place, out of reach of children.

Who Should Avoid Caboxen

Anyone with a recent history of significant bleeding via cough, vomit, stool, or unusual menstrual bleeding
Patients with uncontrolled hypertension
Anyone with an unhealed surgical wound or recent major surgery
Patients currently taking certain antibiotics or drugs with significant CYP3A4 interactions (discuss your full medication list with your oncologist)
Pregnant or breastfeeding patients

Frequently Asked Questions

Why is the dose different for thyroid cancer versus kidney or liver cancer?

Each indication was studied in its own dedicated clinical trial, which established the specific dose that best balances efficacy and tolerability for that cancer type. Medullary thyroid cancer uses a higher 140 mg dose, while RCC and HCC use 60 mg. Never apply one indication’s dose to another without your oncologist’s explicit instruction.

Why must I stop Caboxen before surgery?

Cabozantinib impairs wound healing and increases bleeding risk, so it must be discontinued at least 28 days before any elective surgery, including dental procedures. Your oncologist and surgeon will coordinate the exact timing for stopping and safely resuming treatment after the wound has fully healed.

Is Caboxen the same as Cabometyx?

Caboxen contains the same active ingredient, cabozantinib, as Cabometyx. It is manufactured by Everest Pharmaceuticals to WHO-GMP certified standards, offering the same clinical mechanism at a significantly lower cost.

How do I order Caboxen through Meds For Cancer?

Contact us via WhatsApp (+880 130 449 8958) or email (info@medsforcancer.com) with your oncologist’s prescription specifying your diagnosis and exact prescribed dose. Our team will verify the prescription, confirm availability and pricing, and arrange secure international shipping under the Named Patient Program.

🛡 Named Patient Program — Regulatory Framework

Meds For Cancer operates as a Named Patient Program (NPP) facilitator. WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid prescription, in countries where the branded product is unavailable or unaffordable.

Clinical References

Choueiri TK, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR). NEJM 2015;373:1814–1823.
Abou-Alfa GK, et al. Cabozantinib in patients with advanced hepatocellular carcinoma (CELESTIAL). NEJM 2018;379:54–63.
FDA Prescribing Information: Cabometyx (cabozantinib). Exelixis, 2023.